Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Savara announced acceptance of an encore oral presentation of long-term IMPALA-2 open-label data on molgramostim in autoimmune pulmonary alveolar proteinosis at CHEST 2026, October 18-21 in Phoenix. A poster presentation covering molgramostim treatment effects in aPAP patients with mild diffusion impairment from the Phase 2/3 IMPALA trial was also accepted, with both presented by Dr. Bruce Trapnell of the University of Cincinnati.
Key figures
- Drug Name
- molgramostim inhalation solution
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.